Identification of an Exosome-Related Signature for Predicting Prognosis, Immunotherapy Efficacy, and Tumor Microenvironment in Lung Adenocarcinoma

Figure 3

Evaluation and validation of the utility of prognostic signature in the training set and validation sets. (a) The risk score distribution plot showed the distribution of high-risk and low-risk LUAD patients in the testing set, GSE68465 set and GSE72094 set. (b) The scatter dot plot showed the outcomes between the survival status and risk score of LUAD patients in the high- and low-group. (c) Heatmap of the 10 ERGs expression profiles in the high-risk and low-risk group in the testing set and two external validation sets, separately.

(a)

(b)

(c)